tetano
Editor, Senior Moderator
Eur J Pharmacol
. 2020 Sep 11;173548.
doi: 10.1016/j.ejphar.2020.173548. Online ahead of print.
COVID-19 associated complications and potential therapeutic targets
Jasmin D Monpara[SUP] 1 [/SUP], Srushti J Sodha[SUP] 2 [/SUP], Pardeep K Gupta[SUP] 2 [/SUP]
Affiliations
Abstract
The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.
Keywords: COVID-19; Clinical trials; Pathophysiology; Pharmacotherapy; SARS-Cov-2.
. 2020 Sep 11;173548.
doi: 10.1016/j.ejphar.2020.173548. Online ahead of print.
COVID-19 associated complications and potential therapeutic targets
Jasmin D Monpara[SUP] 1 [/SUP], Srushti J Sodha[SUP] 2 [/SUP], Pardeep K Gupta[SUP] 2 [/SUP]
Affiliations
- PMID: 32926918
- DOI: 10.1016/j.ejphar.2020.173548
Abstract
The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.
Keywords: COVID-19; Clinical trials; Pathophysiology; Pharmacotherapy; SARS-Cov-2.